Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Funachizumab vs Amgxitinib vs glucocorticoids for active Takayasu arteritis
ChiCTR2600121651Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of vunakizumab and ivarmacitinib in Takayasu arteritis (TAK) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Remission rate at 12 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
vunakizumabivarmacitinib
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on ChiCTR2600121651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121651.